丹红注射液联合依达拉奉治疗急性进展性脑梗死临床研究

Clinical Observation of Danhong Injection Associated with Edaravone on Treating Acute Evolving Cerebral Infarction

目的观察丹红注射液联合依达拉奉治疗急性进展性脑梗死的疗效及安全性。方法选择发病72h内的急性进展性脑梗死病人160例,随机分为治疗组(81例)及对照组(79例),分别给予丹红注射液联合依达拉奉治疗和丹红注射液治疗,观察2周后神经功能缺损评分和日常生活能力评分的变化,随时记录用药的不良反应。结果治疗组神经功能缺损评分较对照组下降明显,两组比较差异有统计学意义(P<0.01),治疗组日常生活能力评分较对照组明显提高,两组比较差异有统计学意义(P<0.01);治疗组显效率及总有效率为61.7%和84.0%,对照组显效率及总有效率为44.3%和67.1%,两组比较有统计学意义(P<0.05)。各项安全性指标检测在正常范围。结论丹红注射液联合依达拉奉治疗急性进展性脑梗死的疗效显著。

Objective To compare the clinical effect of single Danhong Injection with Danhong Injection associated with edaravone on treating the patients with acute evolving cerebral infarction（ECI）. Methods 160 patients with acute evolving cerebral infarction enrolled within 72 hour of onset, were divided into Danhong injection group （the placebo group, n = 79） , combination group of Danhong injection and edaravone injection（n = 81） randomly. Before and after treatmen for two weeks, the clinical nervous function defect degree and activities of daily living （ADL） were evaluated using the nervous defect standard （NDS）and barthel index respectively. Curative effect and side effects were observed too. Results There was a significant difference of the clinical nervous function defect degree of the two groups before and after treatment （P〈0.01）. There was a evident difference of ADL before and after treatment of the two groups （P〈0.01）. The total efficiency and significant efficiency of combination group （61.7% and 84.0%） obviously higher than that（44.3% and 67. 1%）of the other group（P〈0. 05）. There were no obvious side effects in the two groups . Conclusions The clinical effect of combination group is better than Danhong injection group.